Pharmaceutical company Ipca Laboratories today said its consolidated net profit surged twofold to Rs 205.36 crore for the year ended March 2010.
The company had a consolidated net profit of Rs 100.80 in the previous fiscal.
Total income of the company rose to Rs 1,566.58 crore, compared to Rs 1,292.64 crore in the previous fiscal, Ipca Lab said in a statement.
The company has recommended a final dividend of 50 per cent, or Re 1 per share, for the financial year 2009-10.
The drug firm's revenues from Indian formulations business saw a growth of 25 per cent to Rs 597.84 crore in the FY10 against Rs 476.59 crore in the previous fiscal.
Revenues from export business stood at Rs 489.15 crore in FY10 against 437.17 crore in the previous fiscal.
The company's revenues from active pharmaceutical ingredients (API) stood at Rs 141.63 crore, compared to Rs 108.34 crore in the previous fiscal.
Shares of Ipca Laboratories today closed at Rs 263.45 on the BSE, up 2.45 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app